Introduction
The expression of genes is regulated by epigenetic systems not associated with changes in the DNA base sequence, including DNA methylation, histone modification, chromatin remodeling factors, and non-coding RNA [1] . As the gene expression patterns regulated through these epigenetic modifications are faithfully reproduced across cell division, epigenetic modifications play a crucial role in biological phenomena such as development, differentiation, and senescence. Moreover, abnormalities in epigenetic modifications such as DNA methylation and histone modification
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trimethylates histone H3 lysine 27 (H3K27me3) [7, 8] . EED and SUZ12 are necessary factors for recruitment of PRC2 to nucleosomes and histone methyltransferase activity [9, 10] . H3K27me3 formed by PRC2 is a repressive histone modification that induces gene silencing, and PRC1 is recruited to nucleosomes upon recognition of this histone mark. PRC1 is formed of four main constituent factors: Ring1A/B, PCGF, CBX, and PHC. Ring1A/B has ubiquitin ligase activity and ubiquitinates histone H2A at lysine 119 [11] . CBX is a chromodomain protein that contributes to recognition of H3K27me3 and recruitment of PRC1 to nucleosomes [12] . PCGF (MEL18, BMI1) is a cofactor of Ring1A/B that increases the ubiquitin ligase activity of Ring1A/B [13] . The ubiquitinated H2AK119 formed by PRC1 plays a central role in repressing the transcription of Polycomb target genes and has been shown to repress transcription by RNA polymerase II [14] . Moreover, PRC1 can condense chromatin and is believed to function as another mechanism of repressing transcription [15] . Many recent studies have shown that constituent factors of PRC1 and their patterns of combination are diverse and there are even differences in function [16, 17] . Noncanonical PRC1 proteins that do not include CBX but include RYBP or KDM2B are recruited to target sites independently of PRC2 and ubiquitinate H2AK119 [18] . A new model in which ubiquitination of H2AK119 by these noncanonical PRC1 proteins recruits PRC2 to target sites and induces H3K27me3 has also been proposed [19, 20] (Fig. 1 ). It appears that there may be several mechanisms by which PcG proteins approach chromatin target sites. Several Polycomb response elements (PREs) that are recognized by PcG proteins have been discovered in Drosophila. PREs have also been found in mice [21] , but have only been mentioned in a few studies. One study in mice involving analysis using ES cells showed that PRC1 and PRC2 accumulate in domains with a high density of unmethylated CpG motifs [22] . Actually, whereas canonical PRC1 proteins recognize H3K27me3 through CBX, noncanonical PRC1 proteins recognize unmethylated CpG islands through their KDM2B subunit and ubiquitinate H2AK119 [19] . Results of recent studies also indicate that transcription factors including Gata1 [23] , Hic1 [24] , Rest [25] , and the Runx1/CBFβ complex [26] recruit Polycomb complexes to specific target genes. Binding to the non-coding RNAs Xist, HOTAIR, and ANRIL is another recognized mechanism of Polycomb recruitment [27] .
The role of Polycomb group proteins in hematopoietic stem cells
Stem cells are cells that serve as the root of all tissue-forming cell populations because they can self-renew and are pluripotent, meaning that they can differentiate into cells with multiple different functions. Polycomb complexes contribute to the maintenance of stem cells such as ES cells and HSCs by repressing gene expression through histone modification [4, 5] . ES cells have bivalent domains in which repressive histone modification by PRC1/2 and activating histone modification by trithorax-group (TrxG) complexes overlap at the same promoter site of the target gene [22] . These bivalent domains regulate the differentiation of stem cells by controlling the on/off switches for genes regulating differentiation and genes related to the cell cycle. It has also been found that tissue stem cells share bivalent domains and HSCs have them as a system for regulating differentiation [28] .
PRC1 members in hematopoietic stem cells
Analysis of knockout mice has led to many discoveries about the functions of different Polycomb proteins in HSCs ( Table 1 ). The PRC1 subunit Bmi1 is expressed by HSCs and is essential for self-renewal of HSCs. HSCs in Bmi1 knockout mice lack the ability to self-renew, which causes progressive decline in HSCs after birth that leads to death from pancytopenia within 2 months. Transplanted fetal liver HSCs from Bmi1 −/− mice lose their long-term repopulating activity [29, 30] . In contrast, overexpression of Bmi1 in HSCs increases the number of HSCs by accelerating their self-renewal and increases their repopulating activity on transplantation [31] . One mechanism involved in the maintenance of HSC self-renewal by Bmi1 is regulation of expression at the INK4a/Arf locus. This locus encodes p16
INK4a and p19
Arf , two genes that repress the cell cycle. Expression of these genes is markedly enhanced in Bmi1
−/− HSCs [32] . Bmi1 −/− HSCs deficient for these genes partially recover their ability to proliferate. This indicates that the loss of the ability of HSCs to self-renew due to Bmi1 deficiency is at least partially attributable to derepression of expression of p16 INK4a and p19 Arf and the associated arrest of the cell cycle [33] . However, the discovery of the novel Bmi1-binding protein UBAP2L, which regulates HSC activity without repressing the INK4a/Arf locus, suggests the existence of mechanisms independent of INK4a/Arf [34] . Bmi1 has been found to be an important factor in not only self-renewal but also pluripotency of HSCs [35] . In HSCs, the genes Ebf1 and Pax5, which regulate the development of B-lineage cells, are repressed through bivalent domains. Bmi1 deficiency derepresses the expression of these genes and promotes differentiation into B-lineage cells. Therefore, Bmi1 suppresses lineage commitment by stabilizing bivalent domains at the loci of genes that regulate differentiation.
Although Bmi1 and Mel-18 are both members of the PCGF family and their amino acid sequences are highly homologous, Mel-18 has different functions in HSCs.
Whereas Bmi1
−/− fetal liver cells completely lack HSC activity, Mel-18 −/− fetal liver cells exhibit almost normal repopulating capacity [31] . It has even been found that Mel-18 −/− BM cells have a slightly enhanced ability to self-renew [36] . These findings indicate that Mel-18 is not essential in the function of HSCs. However, development of lymphoid cells is markedly disrupted in Mel-18 −/− mice, which suggests that Mel-18 functions in differentiated cells rather than HSCs [37] . These differences in function between Bmi1 and Mel-18 also correspond to differences in their endogenous gene expression patterns, namely, that Bmi1 is expressed in undifferentiated hematopoietic cells whereas expression of Mel-18 increases with cellular differentiation [38] .
The number of HSCs in Rae28-deficient mice progressively decreases during the embryonic stage. Whereas 1 in 20,000 wild type E14.5 fetal liver HSCs exhibits long-term repopulating activity, only 1 in 400,000 Rae28 −/− HSCs does so. Transplantation of a Rae28 −/− fetal liver into a lethally irradiated mouse reduces the number of HSCs and cells of each lineage in bone marrow (BM), which indicates Suz12 Knockout Loss of maintenance of HSCs in fetal liver and BM, maturation arrest in T and B cell development [53] that Rae28 is important in the maintenance of HSC activity [39, 40] . Fetal liver HSCs of mice deficient for Cbx2, a member of the CBX family, do not exhibit any obvious abnormalities and their number and repopulating ability are comparable to those of wild-type mice [31, 41] . However, as with mice deficient for Bmi1, Mel-18, and Rae28, these mice exhibit hypoplasia of the thymus and spleen, and maturation arrest in lymphoid cell development [42] . In addition, the number of BM HSCs and their activity were found to be unaffected in Cbx8 knockout mice [43] .
Ring1B, the catalytic subunit of PRC1, has been shown to serve different functions in different stages of differentiation of hematopoietic cells. Ring1B limits the proliferation of hematopoietic progenitor cells while promoting proliferation of maturing progeny by changing the expression patterns of p16
INK4a and cyclin D2 [44] . Research has shown that Ring1A/B double-knockout ES cells cannot maintain their pluripotent status [45] .
PRC2 members in hematopoietic stem cells
Ezh2, the catalytic subunit of PRC2, has been shown to enhance the proliferative capacity of HSCs in analysis of conditional knock-in mice [46] . In addition, although serial transplantation of hematopoietic cells into mice reduces repopulating activity, HSC exhaustion can be completely prevented by overexpression of Ezh2 [47] . Fetal livers of Ezh2-deficient mice have a lower number of HSCs and defective erythropoiesis, which lead to fetal death from anemia. However, adult BM cells of Ezh2 conditional knockout mice only exhibit maturation arrest in T and B cell development, without any obvious impact on HSC function [48] [49] [50] . The H3K27me3 level is lower in fetal liver cells of Ezh2-deficient mice, but is almost normal in adult BM. This suggests that the level is supplemented by the homolog Ezh1 in adult BM HSCs. Actually, whereas Ezh2 is expressed ubiquitously, Ezh1 expression is much higher in BM Lin − Sca1 + c-Kit + (LSK) cells, particularly HSCs, than fetal liver LSK cells, a finding that supports that Ezh1 functions in BM HSCs [48] . Recent research involving analysis of Ezh1-deficient mice has also demonstrated the importance of Ezh1 in BM HSCs. Fetal livers of Ezh1-deficient mice have a slightly lower number of HSCs, but no issues with maintenance of fetal hematopoiesis. In BM, however, Ezh1 deficiency causes a strong senescence response, leading to marked loss of HSCs through disruption of their ability to self-renew. Decreases in the B cell population and shrinking of the spleen are also observed. Simultaneous loss of Ezh1 and Ink4a causes HSCs to regain their ability to proliferate and survive, which indicates that Ezh1 maintains adult BM HSCs by repressing Ink4a [51] .
Newborn mice with blood cell-specific EED deficiency exhibit leukopenia, anemia, and shrinkage of the spleen, which indicates that Eed is essential in normal hematopoiesis. Long-term (LT) HSCs lose their ability to differentiate, which impedes the differentiation of HSCs into lineagerestricted progenitor cells. Although a decrease in B cells is observed in embryos, there are no obvious changes in the number or percentage of fetal liver HSCs. The above findings illustrate that Eed is necessary for the function of adult HSCs rather than fetal HSCs [52] .
Recent research involving analysis of Suz12 conditional knockout mice has shown Suz12 to be essential in the maintenance of both adult and embryonic HSCs. Loss of Suz12 causes HSCs to lose their ability to self-renew and exhausts the HSC pool. Additionally, although Suz12 is essential in lymphocyte formation, it is not necessary for differentiation of myeloid and megakaryocytic cells [53] .
In summary, many discoveries have been made by analyzing the function of different PRC1/2 members in HSCs, from the perspective of gains and losses of function. However, these components can be combined in diverse patterns, and the impact of differences in pattern on the function of complexes remains unknown.
The roles of Polycomb group proteins in hematological malignancies
It is believed that not only gene mutations and genomic abnormalities but also abnormalities in epigenetic regulatory mechanisms such as DNA methylation and histone modification are involved in carcinogenesis. Many different expression level abnormalities and mutations in PcG genes involved in epigenetic regulation have been reported in various types of cancer including hematological malignancies [54, 55] . This indicates that the breakdown of regulation of expression by PRC1/2 can cause carcinogenesis. This section will cover abnormalities in PcG proteins that have been observed in various types of hematological malignancies (Table 2) and their functions as discovered through experiments in mice.
PRC1 members in hematological malignancies
Bmi1 came to be recognized as a gene involved in carcinogenesis after its isolation as a gene that cooperates with c-myc in the development of lymphomas [56] . High expression of Bmi1 has so far been observed in myelodysplastic syndrome (MDS) [57, 58] , acute myeloid leukemia (AML) [59, 60] , chronic myeloid leukemia (CML) [61, 62] , and various types of lymphoma including diffuse large B cell lymphoma (DLBCL) [63] [64] [65] [66] , and has been shown to be correlated with poor prognosis. Recently, IG-BMI1 has been identified as a new fusion gene that is acquired in the advanced stage of chronic lymphocytic leukemia (CLL) and up-regulates expression of Bmi1 [67] .
Multiple experiments in mouse models have shown that Bmi1 is involved in leukemogenesis and the maintenance of leukemia stem cells (LSCs). The MLL-AF9 fusion gene immortalizes granulocyte/macrophage progenitors (GMPs) and induces the onset of AML when transplanted into irradiated mice, but AML cannot be induced by MLL-AF9 using GMPs derived from Bmi1-deficient mice [68] . It is also not possible to use hematopoietic progenitor cells derived from Bmi1-deficient mice in transformation of hematopoietic progenitor cells by the E2a-Pbx1 fusion gene frequently detected in pre-B lymphoblastic leukemia. Transformation by E2a-Pbx1 is possible in mice deficient for both Bmi1 and Ink4a-Arf, which indicates that increased expression of Ink4a-Arf is why transformation cannot be achieved with progenitor cells from Bmi1-deficient mice [69] . These results indicate that Bmi1 is an important factor in leukemic transformation. HoxA9 and Meis1 are other oncogenes that can induce the transformation of mouse BM cells. However, when Bmi1 −/− fetal liver cells forced to express these genes are transplanted into irradiated mice, they can only induce AML in primary transplantation and not in secondary transplantation [29] . These results indicate that Bmi1 is essential in the maintenance of repopulating LSCs in mice.
Results of many studies suggest that Bmi1 is also involved in the progression of CML. The expression level of Bmi1 is higher in advanced-phase patients than in chronic-phase patients, with the expression level at diagnosis correlating with time until transformation to blast crisis [61] . Overexpression of BMI1 in CD34 + cells derived from CML patients enhances their proliferative activity and selfrenewal properties in vitro, and also enhances the potential for leukemic transformation when transplanted into immunodeficient mice [70] . These results suggest that Bmi1 may collaborate with BCR-ABL in the malignant transformation of leukemia cells. The synergistic effects of Bmi1 and BCR-ABL have also been observed in mouse models of B-progenitor acute lymphoblastic leukemia (B-ALL) initiation from CML B lymphoid progenitors [71] .
High expression of Cbx7 has been found in follicular lymphoma. When expression of Cbx7 was forced in HSCs in an in vivo experiment, Cbx7 cooperated with c-myc to produce T-cell and B-cell lymphomas [72] . Cbx8 has been shown to be essential in the onset of MLL-AF9-induced leukemogenesis in AML. Cbx8 binds to MLL-AF9, and it is possible to prevent MLL-AF9-induced transformation by inhibiting that binding with point mutations or knockdown of Cbx8 [43] .
High expression of Ring1A has been observed in MDS and AML and has been shown to be related to poor prognosis [58] . Additionally, SNPs in Ring1A have been found to be strongly associated with risk for non-Hodgkin lymphoma [73] .
Although many such discoveries have been made about the functions of constituent factors of PRC1 in MDS/MPN Loss-of-function mutation [83] Suz12 T-ALL, ETP-ALL Loss-of-function mutation/deletion [79, 80] MDS/MPN Loss-of-function mutation [83] hematological malignancies, it is not known how Ring1A and Ring1B, which form the active center of PRC1, function in hematological malignancies. Therefore, we performed an experiment to determine the functions of Ring1A and Ring1B in AML. We investigated if irradiated wildtype mice would develop AML, when administered tamoxifen (or a control of corn oil) after transplantation of cKit + BM-derived cells from Ring1A/B double-knockout mice (Ring1A
F/F , CreETR2), into which MOZ-TIF2 or MLL-AF10 had been introduced. We found that whereas all mice in the control group developed AML and died, all mice in the group administered tamoxifen survived. When we analyzed leukemia cells after administering tamoxifen, we found that the LSC fraction had decreased, differentiation had been induced, and AML did not repopulate when cells were re-transplanted into other mice. These results indicate that Ring1A and Ring1B are essential in the onset of AML induced by MOZ-TIF2 and MLL-AF10, and in the maintenance of LSCs (manuscript in preparation).
PRC2 members in hematological malignancies
High Ezh2 expression has been observed in MDS, AML, and B-cell and T-cell lymphomas [58, 63, 64, 74, 75] . In addition, mutation in tyrosine residue 641 of the SET domain, which is the catalytic site of Ezh2, is detected in 7.2 % of patients with follicular lymphoma (FL) and 21.7 % of patients with DLBCL [76] . Mutants with this gain-of-function mutation have been found to have higher di-and tri-methylation of H3K27 than the wild type [77] . Mutation in alanine residue 677 has also been reported as a similar functional mutation in DLBCL [78] . The results of these studies suggest that up-regulation of Ezh2 contributes to tumorigenesis and thus, Ezh2 functions as an oncogene.
Conversely, loss-of-function mutations in Ezh2 and other constituent factors of PRC2 as well as loss of these genes have also been reported in various hematological malignancies, which indicates that Ezh2 also serves as a tumor suppressor gene. Loss-of-function mutations or deletions in Ezh2 or Suz12 have been detected in a respective 18 and 7 % of patients with T-cell acute lymphoblastic leukemia (T-ALL) [79] . Loss of Ezh2, EED, or Suz12 or sequence mutations in any of these genes have been detected in 42.2 % of patients with early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) [80] . Various homozygous and heterozygous loss-of-function mutations in Ezh2 have also been observed in MDS, MDS/myeloproliferative neoplasms (MPN), and myelofibrosis [81, 82] . Loss-of-function mutations in Suz12 and EED have also been detected in MDS/MPN, though they are infrequent [83] . These findings suggest that functional inhibition of PRC2 may promote tumor formation.
In summary, Ezh2 plays dual roles in the process of carcinogenesis, functioning as both an oncogene and a tumor suppressor gene. This functional duality of Ezh2 has also been demonstrated in experiments in mouse models. Several experiments in which mice were observed long-term after loss of Ezh2 in hematopoietic cells showed that this loss leads to development of heterogeneous malignancies including T-ALL, MDS, and MDS/MPN [84] [85] [86] . These results indicate that Ezh2 functions as a tumor suppressor gene in the pathogenesis of T-ALL and MDS-related diseases. Ezh2 has also been found to play an oncogenic role in lymphoma and AML. A recent study showed that Ezh2 Y641F , which is detected as a gain-of-function mutation in FL and DLBCL, strongly promotes the development of lymphoma in mice by collaborating with c-Myc [87] . Ezh2 is believed to be important in leukemogenesis because, loss of Ezh2 decreases the proliferative ability of leukemia cells and induces differentiation, delaying the onset of AML induced by the MLL-AF9 fusion gene in mice [88, 89] .
Targeted therapy against Polycomb members
As discussed in the previous sections, abnormalities related to PcG proteins, including abnormal expression levels and mutations, have been observed in specimens from various types of hematological malignancies, and the dependency of these malignancies on Polycomb proteins has been demonstrated in mouse models. These findings have sparked an increasing interest in PcG proteins as therapeutic targets in recent years. Actually, several research groups have discovered low molecular weight compounds that inhibit the enzymatic activity of Ezh2 and show a strong antitumor effect in cell lines and xenograft models of lymphoma with gain-of-function mutations in Ezh2 [90] [91] [92] . Another compound that was discovered is stabilized α-helix of EZH2 peptide (SAH-EZH2), which decreases the H3K27me3 level by inhibiting binding of Ezh2 and EED. Treatment of MLL-AF9 leukemia cells with SAH-EZH2 arrests proliferation and induces monocyte-macrophage differentiation, which suggests that drugs that inhibit Ezh2 are effective against AML that is dependent on Ezh2 expression [93] .
Concluding remarks
This paper covered the functions of PcG proteins in normal hematopoiesis and in various hematological malignancies. PcG proteins play a major role in the maintenance of normal HSCs. Depending on the type of hematopoietic malignancy, they can function as oncogenes, tumor suppressor genes, or even both. The functions of PcG proteins differ not only between hematological malignancies but also between various solid tumors, and various PcG protein abnormalities such as overexpression, decreased expression, and mutation are observed. Ezh2 inhibitors have been found effective against lymphoma and AML, cancers in which Ezh2 has been experimentally demonstrated to act as an oncogene. This indicates that it is important to understand how PcG proteins function in different types of cancer. Hopefully, effective treatments against various diseases will be developed as more information about mechanisms of PcG protein involvement in carcinogenesis is uncovered.
